237 related articles for article (PubMed ID: 29219615)
1. Therapy sequencing strategies in multiple myeloma: who, what and why?
Costello C; Mikhael JR
Future Oncol; 2018 Jan; 14(2):95-99. PubMed ID: 29219615
[No Abstract] [Full Text] [Related]
2. Multiple myeloma--translation of trial results into reality.
Moreau P; Rajkumar SV
Lancet; 2016 Jul; 388(10040):111-3. PubMed ID: 27411865
[No Abstract] [Full Text] [Related]
3. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions.
Moreau P; de Wit E
Br J Haematol; 2017 Oct; 179(2):198-218. PubMed ID: 28556890
[TBL] [Abstract][Full Text] [Related]
4. The effect of novel therapies in high-molecular-risk multiple myeloma.
Lancman G; Tremblay D; Barley K; Barlogie B; Cho HJ; Jagannath S; Madduri D; Moshier E; Parekh S; Chari A
Clin Adv Hematol Oncol; 2017 Nov; 15(11):870-879. PubMed ID: 29200420
[TBL] [Abstract][Full Text] [Related]
5. [Molecular targeting agents for multiple myeloma].
Fujii S; Abe M
Nihon Rinsho; 2012 Nov; 70 Suppl 8():518-23. PubMed ID: 23513894
[No Abstract] [Full Text] [Related]
6. Drugs: More shots on target.
Appel A
Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
[No Abstract] [Full Text] [Related]
7. Maintenance therapy and need for cessation studies in multiple myeloma: Focus on the future.
Diamond B; Maclachlan K; Chung DJ; Lesokhin AM; Ola Landgren C
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101140. PubMed ID: 32139006
[TBL] [Abstract][Full Text] [Related]
8. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
9. [Current status of clinical trials of novel agents for multiple myeloma].
Kuroda J
Rinsho Ketsueki; 2014 Oct; 55(10):2005-15. PubMed ID: 25297766
[No Abstract] [Full Text] [Related]
10. [Development of novel agents for multiple myeloma; now and the future].
Hata H
Rinsho Ketsueki; 2011 Aug; 52(8):603-8. PubMed ID: 21897065
[No Abstract] [Full Text] [Related]
11. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
12. An oral proteasome inhibitor for multiple myeloma.
Pratt G
Lancet Oncol; 2014 Dec; 15(13):1417-1418. PubMed ID: 25456357
[No Abstract] [Full Text] [Related]
13. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
14. Triplet vs. doublet drug regimens for managing multiple myeloma.
Offidani M; Corvatta L; Gentili S
Expert Opin Pharmacother; 2018 Feb; 19(2):137-149. PubMed ID: 29265901
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in multiple myeloma: Current and emerging targets and mechanisms of action.
Wudhikarn K; Wills B; Lesokhin AM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101143. PubMed ID: 32139009
[TBL] [Abstract][Full Text] [Related]
16. [Multiple myeloma].
Iida S
Rinsho Ketsueki; 2012 Feb; 53(2):155-63. PubMed ID: 22450574
[No Abstract] [Full Text] [Related]
17. Pooled analysis of the reports of carfilzomib, panobinostat, and elotuzumab combinations in patients with refractory/relapsed multiple myeloma.
Liu L; Zhao N; Xu W; Sheng Z; Wang L
J Hematol Oncol; 2016 Jul; 9(1):54. PubMed ID: 27405295
[TBL] [Abstract][Full Text] [Related]
18. Novel therapies in monoclonal gammopathies.
Niesvizky R
Hematology; 2012 Apr; 17 Suppl 1():S121-4. PubMed ID: 22507798
[TBL] [Abstract][Full Text] [Related]
19. FDA approves new agent for multiple myeloma.
Fenichel MP
J Natl Cancer Inst; 2015 Jun; 107(6):djv165. PubMed ID: 26032612
[No Abstract] [Full Text] [Related]
20. Novel therapeutics in multiple myeloma.
Stewart AK
Hematology; 2012 Apr; 17 Suppl 1(0 1):S105-8. PubMed ID: 22507794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
